.Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA05_Fluticasone.Fluticasone .Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BA05_Fluticasone.Fluticasone| name: | Fluticasone |
| ATC code: | R03BA05 | route: | inhalation |
| n-compartments | 2 |
Fluticasone is a synthetic corticosteroid used as an anti-inflammatory and immunosuppressive agent, primarily for the management of asthma and allergic rhinitis. Administered via inhalation, it reduces airway inflammation. Widely approved and in clinical use globally.
Pharmacokinetic parameters reported in healthy adult volunteers after inhaled administration.
Soulele, K, et al., & Karalis, V (2015). Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 80 33–42. DOI:10.1016/j.ejps.2015.08.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26296862
Siederer, S, et al., & Yang, S (2016). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. European journal of drug metabolism and pharmacokinetics 41(6) 743–758. DOI:10.1007/s13318-015-0303-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474864
Allen, A, et al., & Yang, S (2016). Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. International journal of clinical pharmacology and therapeutics 54(4) 269–281. DOI:10.5414/CP202438 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26902504